BCC 2023 | Early breast cancer: do we need chemotherapy in low genomic/high clinical risk (ER+/HER2-)?

Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, talks on whether chemotherapy is required in ER+/HER2- early breast cancer patients with low genomic/high clinical risk, highlighting the node positive population where no advantage to chemotherapy in post-menopausal women was observed. This interview took place at the St. Gallen International Breast Cancer Consensus Meeting in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.